Differences in the structural features of atypical adenomatous hyperplasia and low-grade prostatic adenocarcinoma

Ahmet Midi, Tülay Tecimer, Süheyla Bozkurt, Naziye Özkan
Department of Pathology, Marmara University Hospital, Istanbul, Turkey

ABSTRACT

Aim: Atypical adenomatous hyperplasia (AAH) is a small glandular proliferation that has histological similarities with Gleason grade 1 and 2 prostatic adenocarcinoma (PACG1,2). There are no distinct histomorphological criteria distinguishing these two lesions from each other and other small glandular proliferations. Because treatment approaches are different for these lesions, it is necessary to determine histological criteria. The aim of this study is to review the histological features of these two lesions and to define new histological criteria distinguishing AAH from PACG1,2. We, therefore, assessed 18 anatomical and structural parameters.

Materials and Methods: We found 11 AAH (22 foci) and 15 PACG1,2 (22 foci) cases in 105 radical prostatectomy specimens. Basal cell-specific antikeratin was applied to these lesions. We assumed that PACG1,2 lesions did have not basal cells and we grouped the lesions as AAH and PACG1,2 based on this assumption.

Results: We found differences between AAH and PACG1,2 lesions for some parameters including the number of glands, structures such as the main ductus and basal cells. We found similar properties in the two lesions for the following parameters: localization, multiplicity, diameter of the lesion, focus asymmetry, distance between glands, inflammatory cells in and out of the lesions, secretory cell shape on the luminal side, papillary projection towards the luminal side of gland, the shape of the outer gland, the infiltrative pattern of the gland, glandular pleomorphism, biggest gland diameter and median gland diameter.

Conclusion: We determined that concurrent evaluation of histomorphological features was important to differentiate between AAH and PACG1,2.

Key words: Adenosis, cancer, hyperplasia, low grade, proliferations, prostate, small glandular

INTRODUCTION

Atypical adenomatous hyperplasia (AAH) is a generally well-defined lesion characterized by the proliferation of small glands in the prostate. The incidence is reported as 1.6-36.9%. They are seen most commonly in the transitional zone. The lesion has been named AAH,[1-22] adenosis[23-27] and atypical hyperplasia[28] in various reports. The AAH focus is usually found in the periphery or centre of the hyperplastic nodule. Low magnification shows uniform small glands with a lobular growth pattern. It usually has a prominent and smooth border, but there may be focal irregularities resembling invasion. The AAH consists of cuboidal or columnar cells with pale or clear cytoplasm. The nucleus is round and located at the basal part of the cell. There is a granular chromatin structure resembling normal prostatic cells. There are often small nucleoli. Basal cells are vaguely defined.[30-32]

Gleason grade 1 prostatic adenocarcinoma (PACG1) is defined as a lesion consisting of monotonous glands of moderate size with minimal stromal invasion, which enlarge by pushing surrounding structures and resemble benign glands with their cytoplasmic features. Gleason grade 2 prostatic adenocarcinoma (PACG2) lesions show infiltrative findings and mild variability in gland size in addition to the features of PACG1.[33,34]

There are many studies on the diagnostic criteria of AAH and its differentiation from adenocarcinoma.[17,35-42] The main criteria arising from these studies are nucleolus size, anti-keratin immunohistochemistry staining (34βE12) specific for basal cells, appearance of the luminal border of the gland and the presence of acidic mucin. However, additional criteria are required when these prove inadequate.

The aim of our study was to assess a total of 18 characteristics consisting of additional structural (glandular, stromal) criteria in addition to the histological criteria for the...
differentiation of AAH and well-differentiated prostatic adenocarcinoma and to integrate the parameters that can be used to differentiate between these two lesions.

MATERIALS AND METHODS

Case selection
We included a total of 105 radical prostatectomy materials evaluated consecutively at the Marmara University, Medical Faculty, Department of Pathology between October 1999 and September 2004. The materials were re-evaluated and those containing AAH or PACG1,2 lesions selected. Three cases consisting of small glands that did not have adequate tissue representing the lesion after the serial sections were excluded from the study and 11 cases of AAH (22 foci) and 15 cases of PACG1,2 (22 foci) were included.

Sections, 4 μm thick, were obtained from the paraffin blocks of the PACG1,2 lesions where the diagnosis was in doubt and all AAH lesions, and the 34βE12 immunohistochemistry stain was used to show basal cells.

Parameters evaluated
We evaluated the AAH and PACG1,2 lesions by dividing them into four groups according to 18 anatomical and structural parameters. These groups and the parameters are shown in Table 1.

Evaluation
Evaluation of the parameters related to the anatomical features
We determined lesion localization according to proximal or distal placement to the verumontanum. All classifications dividing the prostate into various regions accept the distal section of the verumontanum as PZ. All radical prostatectomy material was evaluated following sectioning in our laboratory. The sections were made vertical to the urethra with the apex coded A and the following sections as B, C, D in sequence. We accepted sections A and B of the sections distal to the verumontanum as the peripheral zone.

Multiplicity is the presence of more than one lesion with the same features in a case.

Evaluation of the parameters related to structural features
Evaluations of the parameters related to structural features are shown in Table 2.

We evaluated the secretory cell luminal gland parameter and the irregularity formed at the apical side of the cytoplasm due to the size variability of the cells forming the same gland. This irregularity due to the difference in secretory activity was converted into a numerical value between 0 and 2.

When determining the mean gland diameter, we measured the diameter of all randomly selected glands in an area magnified 20 times and entered the data into the Microsoft Excel 2000 program database to calculate the mean diameter.

Evaluation of the immunohistochemical features (the presence of basal cells)
We used 34βE12 to show the presence of basal cells in the AAH and PACG1,2 lesions. The lesions were assessed as continuous, focal discontinuous, diffuse discontinuous and none depending on the staining.

Statistical Evaluation
The data obtained from the study were entered into the database and analyzed with the Statistical Package for Social Sciences for Windows, version 11.0 (SPSS) software program.

The Mann-Whitney U-test was used to evaluate the numerical parameters (mean largest gland diameter, mean gland diameter, lesion width and lesion length parameters) between the types.

The χ²-test was used to compare the non-numerical values between the types. The glandular shape difference, gland luminal side, gland infiltrative pattern (angulation of gland outer side), number of glands comprising the lesion, the relation of the gland to its surroundings (focus asymmetry), the presence of intralesional and perilesional inflammatory cells, lobular pattern and main ductus parameters were evaluated statistically.

We used Fisher’s exact probability test, a subgroup of the χ² relation test, when evaluating the four-celled tables where the expected value was <5 (the distance between the glands).

The results were interpreted at the P < 0.05 significance level.

Table 1: Grouping of evaluated parameters

| Anatomical features                      | Localizations, multiplicity                        |
|----------------------------------------|---------------------------------------------------|
| Structural and structure-correlated features |                                      |
| Diameter of lesion, number of glands, focus asymmetry, lobular pattern, main ductus-like structure, distance between glands, inflammatory cells in-and-out of lesions |
| Secretory cell shape on luminal side, papillary projection towards the luminal side of the gland, the form of the outer part of the gland, infiltrative pattern of the gland, glandular pleomorphism, biggest gland diameter, median diameter of gland |
| Existence of basal cells                |                                      |

Midi et al.: Differences in the structural features of AAH and PACG1,2
**Immunohistochemical staining method**

\(34\beta E12\) (Keratin, HMW Ab-3 (1/50; Clone 34 \(\beta\) E12; MS-1447-S1; Neomarkers).

We used the streptavidine biotin/horseradish peroxidase (Str.AB/HRP) method to show keratin expression. Ultra V Block (Ultra Vision Kit; TP-125-HL; Lab Vision) drops on the slides were used to prevent nonspecific staining. The tissues were incubated for 10 min in biotinylated secondary antibody (Ultra Vision Kit; TP-125-HL; Lab Vision). Streptavidine Peroxidase (Ultra Vision Kit; TP-125-HL; Lab Vision) was then used. DAB (TA-125-HD, Lab Vision) was used as a chromogen. Cytoplasmic brown staining in basal cells was interpreted as positive.

### RESULTS

The AAH was present at a rate of 10.5% (11 cases) and PACG1,2 at a rate of 15.2% (15 cases) in the 105 radical prostatectomy material were studied [Table 3]. We had 22 cases each of AAH and PACG1,2. It has been found that 63.7% of the AAH lesions (14/22) and 50% of the PACG1,2 lesions (11/22) were localized distal to the verumontanum (A and B sections).

Four AAH cases were unifocal (63.7%) and four multifocal (36.3%) (maximum 6 foci). While 11 of the PACG1,2 cases were unifocal (73.4%) and 4 (26.6%) were multifocal (maximum 4 foci) [Figure 1]. The AAH and PACG1,2 were present together in two cases.

There was no significant difference between the multiplicity and frequency parameters of the AAH and PACG1,2 lesions when evaluated with the Mann-Whitney U-test \((P > 0.05)\).

Our results showed that PACG1,2 lesions consisted of a larger number of glands [Table 4]. This result was found to be statistically significant \((P = 0.01)\). We found that this significance was due the higher number of lesions with 10-30 glands in AAH.

A lobular pattern was present in 59.1% of AAH lesions and 9.1% of PACG1,2 lesions [Figures 2 and 3] and this was found to be statistically significant \((P = 0.01)\).

A main ductus-like structure was present in 86.4% of the AAH cases [Figure 4] but not in the PACG1,2 lesions. This

---

**Table 2: Evaluation of the parameters of the structural and structure-related features**

| Parameters of lesion-related features | Quantitative evaluation with ocular micrometer (µm) |
|--------------------------------------|---------------------------------------------|
| Diameter of the lesion               | (1) <10 (2) 10-30 (3) 30-50 (4) >50          |
| Number of glands, Quantitative       |                                             |
| Focus asymmetry, relative            | (1) Smooth lesion (2) Slightly (3) Hardly    |
| Lobular pattern, main ductus-like structure (relative) | (1) (+) (2) (+) |
| Distances between glands relative    | (1) No distance between glands (2) 1-3 stromal cells between glands |
| Inflammatory cells in and out of lesions semiquantitative | (1) (-) (2) Minimal (3) Many |

**Parameter of the gland features**

| Secretory cell shape on luminal side | (0) Smooth (cytoplasm dimension is equivalent) (1) Slightly irregular (2) Very irregular |
|-------------------------------------|--------------------------------------------------------------------------------------|
| Papillary projection towards the luminal side of gland (relative) | (1) Smooth (2) Glands with slight papillary projection towards the luminal side |
| The form of the outer gland outside (relative) | (1) Smooth (2) Slightly papillary projection towards the outside |
| Infiltrative pattern of gland (relative) | (1) No angulation (gland appearance is round) (2) Slight angulation in the glands (ellipsoid appearance) |
| Glandular pleomorphism, (relative) | (0) (-) (1) Mild (2) Significant |
| The biggest gland diameter, median diameter of gland | Quantitative evaluation with ocular micrometer (µm) |

**Table 3: Anatomical features of the AAH and PACG1,2 lesions**

| Parameter | Data number/Lesion number | Frequency | Localization, VP (%)/VD (%) | Multiplicity (%) |
|-----------|---------------------------|-----------|----------------------------|-----------------|
| AAH       | 22.Ka s                   | 10.50%    | 8 (36.3)/14 (63.4)         | 4 (36.3)        |
| PACG1,2   | 15/22                     | 15.20%    | 11 (50)/11 (50)            | 4 (26.6)        |

OS: Data number, LS: Lesion number, Loc: Localization, VP: Proximal to verumontanum, VD: Distal to verumontanum.
result is statistically very significant ($P = 0.0001$).

The distance between the glands was higher in AAH, but the result was not statistically significant ($P > 0.05$).

The lesion size (length, width), the relation of the lesion to its surroundings (focus asymmetry) [Figures 5 and 6] and the presence of intralesion and perilesional cells parameters were similar for the
groups and there was no statistically significant difference \((P > 0.05)\).

Table 5 presents the comparative glandular features of the AAH and PACG1,2 lesions and the statistical results.

The secretory gland luminal side [Figure 7] and an infiltrative-type gland (angulation of gland external side) was seen more often in PACG1,2 lesions but the difference was not statistically significant [Figures 8 and 9] \((P > 0.05)\).

Papillary projection into the gland lumen was observed more commonly with AAH but there was no significant difference \((P > 0.05)\).

Results for glandular pleomorphism (size variability of glands), mean largest gland diameter, mean gland diameter, shape of gland exterior parameters were similar between the groups with no statistical difference \((P > 0.05)\).

Basal layer cells were present in 50% of AAH lesions in a discontinuous manner and in 50% as diffuse discontinuous. No basal layer cells were observed in PACG1,2 lesions [Figures 10 and 11]. The result was markedly significant \((P = 0.00001)\).

**DISCUSSION**

A common problem in pathology is evaluating prostatic

---

**Table 4: Comparison of the AAH and PACG1,2 lesions in terms of parameters of the lesion features and statistical results**

| Histological parameters | Evaluation | AAH number (%) | PACG1,2 number (%) | Applied test; \(P\) |
|-------------------------|------------|----------------|-------------------|---------------------|
| Lesion diameter         | Microns    | 1306 ± 634 (500-2500 µm) | 1710 ± 1197 (500-5000 µm) | Mann-Whitney; \(P > 0.05)\ |
| Lesion dimensions       | Micron     | 2252 ± 1021 (1000-4250 µm) | 2715 ± 1380 (1000-6250 µm) | Mann-Whitney; \(P > 0.05)\ |
| Number of glands        | Between 10 and 30 | 6 (27.2) | 1 (4.5) | Mann-Whitney; \(P > 0.05)\ |
|                        | Between 30 and 50 | 9 (40.9) | 11 (50) | Mann-Whitney; \(P > 0.05)\ |
|                        | > 50        | 7 (31.8) | 10 (45.4) | Mann-Whitney; \(P > 0.05)\ |
| Focus asymmetry         | Regular    | 8 (36.3) | 9 (40.9) | \(\chi^2\) test; \(P > 0.05)\ |
|                        | Slightly irregular | 9 (40.9) | 5 (22.7) | \(\chi^2\) test; \(P > 0.05)\ |
|                        | Markedly irregular | 5 (22.7) | 8 (36.3) | \(\chi^2\) test; \(P > 0.05)\ |
| Lobular pattern         | None       | 9 (40.9) | 20 (90.9) | \(\chi^2\) test; \(P = 0.01)\ |
|                        | Absent     | 13 (59.1) | 2 (9.1) | \(\chi^2\) test; \(P = 0.01)\ |
| Main ductus-            | Present    | 3 (13.6) | 22 (100) | Fisher exact probability test; \(P = 0.0001)\ |
| like structure          | Present    | 19 (86.4) | 0 (0) | Fisher exact probability test; \(P = 0.0001)\ |
| Distance between glands | Absent     | 15 (68.1) | 18 (81.8) | Fisher exact probability test; \(P = 0.005)\ |
|                        | Minimal    | 7 (32.8) | 4 (18.1) | Fisher exact probability test; \(P = 0.005)\ |
|                        | Marked     | 0 (0) | 0 (0) | Fisher exact probability test; \(P = 0.005)\ |
| Inflammatory cells in lesions | Absent     | 6 (27.3) | 4 (18.1) | \(\chi^2\) test; \(P > 0.05)\ |
|                        | Minimal    | 15 (68.2) | 18 (81.9) | \(\chi^2\) test; \(P > 0.05)\ |
|                        | Many       | 1 (4.5) | 0 (0) | Fisher exact probability test; \(P > 0.05)\ |
| Inflammatory cells out of lesions | Absent     | 0 (0) | 0 (0) | Fisher exact probability test; \(P > 0.05)\ |
|                        | Minimal    | 16 (72.7) | 14 (63.6) | Fisher exact probability test; \(P > 0.05)\ |
|                        | Many       | 6 (27.3) | 8 (36.4) | Fisher exact probability test; \(P > 0.05)\ |

**Table 5: Comparison of the AAH and PACG1,2 lesions in terms of parameters of the gland features and statistic results**

| Parameters                      | Evaluation | AAH, number (%) | PACG1,2, number (%) | Test used |
|---------------------------------|------------|----------------|-------------------|-----------|
| Secretory cell shape            | Straight (equal cytoplasmic dimensions) | 5 (22.7) | 9 (40.9) | \(\chi^2\) test; \(P > 0.05)\ |
|                                 | Slightly irregular | 6 (27.3) | 6 (27.3) | \(\chi^2\) test; \(P > 0.05)\ |
|                                 | Markedly irregular | 11 (50) | 7 (31.8) | \(\chi^2\) test; \(P > 0.05)\ |
| Papillary projection            | Absent     | 5 (22.7) | 11 (50) | \(\chi^2\) test; \(P > 0.05)\ |
| towards the luminal side        | Minimal projections | 14 (63.7) | 8 (36.4) | \(\chi^2\) test; \(P > 0.05)\ |
| side of gland                   | Marked     | 3 (13.6) | 3 (13.6) | \(\chi^2\) test; \(P > 0.05)\ |
| Shape of the outer of gland     | Minimal invaginations | 13 (59.3) | 11 (50) | \(\chi^2\) test; \(P > 0.05)\ |
|                                 | Marked     | 3 (13.6) | 3 (13.6) | \(\chi^2\) test; \(P > 0.05)\ |
| Infilitrative pattern of glands | No angulation | 15 (68.1) | 8 (36.3) | \(\chi^2\) test; \(P > 0.05)\ |
|                                 | Minimal angulation | 5 (22.7) | 9 (40.9) | \(\chi^2\) test; \(P > 0.05)\ |
|                                 | Marked angulation | 2 (9.0) | 5 (22.7) | \(\chi^2\) test; \(P > 0.05)\ |
| Glandular pleomorphism          | None       | 1 (4.5) | 7 (32.8) | \(\chi^2\) test; \(P > 0.05)\ |
|                                 | Mild       | 7 (32.8) | 5 (22.7) | \(\chi^2\) test; \(P > 0.05)\ |
|                                 | Marked     | 14 (63.6) | 10 (45.4) | \(\chi^2\) test; \(P > 0.05)\ |
| Biggest gland diameter          | Micron     | 478 ± 311 (100-1250 µm) | 407 ± 169 (140-650 µm) | Mann-Whitney; \(P > 0.05)\ |
| Median diameter of gland         | Micron     | 111 ± 46 (30-225 µm) | 117 ± 47 (60-250 µm) | Mann-Whitney; \(P > 0.05)\ |
lesions composed of small acini with suspected malignancy some cancers have been diagnosed as benign lesions while some benign lesions have been diagnosed as cancer especially following needle biopsy due to the inadequacy of the tissue representing the lesion and the absence of histological criteria.

The incidence of AAH varies between 1.6 and 36.9% in reports according to the material studied. We did not come across any English articles on the incidence of PACG1,2 lesions. Our values were 10.4% for AAH and 14.3% for PACG1,2. The rates do not reflect the actual incidence as we evaluated the radical prostatectomy material from grade 3 or higher cancers in our study. Studies on autopsy material are therefore needed.

The AAH and PACG1,2 lesions are seen more frequently in TZ. A localization close to the apex and the periurethral area are reported to be common sites for AAH. We felt that it would not be possible to definitely differentiate between PZ, SZ and TZ in the area proximal to the verumontanum taking the anatomical classifications into account. The minimum frequency in the peripheral zone was 63.4% for AAH and 50% for PACG1,2.
The AAH and PACG1,2 lesions have a tendency to be multifocal. This rate changes according to how the material was obtained, but the rate has been reported as 16% in needle biopsies, 68% in TUR material and 46% in prostatectomy material for AAH. Bostwick et al. have reported the rate of lesion multifocality as 58% in AAH and 38% in PACG1,2 in their study that also included transurethral resection material. The AAH and PACG1,2 cases were similar for multiplicity in our study with a frequency of 36% for AAH and 26% for PACG1,2. These rates are consistent with other reports and it is therefore not possible to use multiplicity as a criteria for differentiating between AAH and PACG1,2.

We did not come across any reports on the number of glands in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We did not come across any reports on the number of glands in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was markedly higher in PACG1,2 and AAH lesions. We determined the number of glands comprising the lesion was marked...
The PACG1,2 is reported to consist of monotonous glands and AAH of more heterogeneous glands. However, the mean gland size and glandular pleomorphism have not been found useful in other studies in differentiating AAH from adenocarcinoma. Montironi et al. have found mild shape variability in 25 and 75% of the glands in AAH and cancer and marked shape variability in 75 and 25%, respectively. Glandular pleomorphism was found in 95% of AAH lesions and 68% of PACG1,2 lesions, but there was no statistical significance.

Our study is the first to evaluate the largest gland diameter and the mean gland diameter in a comparative way. There is one previous study where the gland diameter was measured in PACG1,2 lesions. The largest gland diameter was in AAH in our study while the mean gland diameter was larger in PACG1,2 lesions. The results are similar with no statistical significance. We felt that these criteria could not be used in the differential diagnosis of AAH and PACG1,2 lesions.

Another important criterion in the differentiation of AAH and PACG1,2 lesions is the presence of basal cells. Staining of basal cells with 34βE12 enables differentiating many lesions. Cells staining specifically with 34βE12 are not present in cancers and are seen characteristically in an interrupted manner in AAH. A few studies have reported a positive immunoreaction of neoplastic cells with 34βE12. However, it has been reported that the antigen recovery method may be responsible for the positive staining. Another study has reported that the few cells staining positively with 34βE12 did not morphologically resemble basal cells at all. All basal cells of the normal prostatic gland show strong immunoreactivity with 34βE12, but there may be disturbed staining continuity in inflammation. Formalin fixation and heat damage can also cause false negativity in basal cells and the absence of staining in some basal cells while others are stained, especially in needle biopsies and other biopsies where the material is small makes the diagnosis difficult. We confirmed this morphological finding with 34βE12 and observed the presence of basal cells in all AAH lesions in the gland periphery while there was no positively staining cell in PACG1,2 lesions. Positively staining basal cells were present in a focal manner in 50% of AAH lesions and diffuse in 50%.

In conclusion, the absence of basal cells in PACG1,2 and their occasional presence in AAH was accepted as the most important diagnostic criterion. A lobular pattern, stated as one of the most important features in histologically differentiating AAH and PACG1,2, was significantly higher in AAH lesions but was also found, albeit at a lower rate in PACG1,2 lesions. Although it is reported that a gland with a straight luminal side is important for PACG1,2 lesions, we did not find a significant difference between AAH and PACG1,2 lesions.

Although a lobular pattern and the presence of basal cells are important parameters for the differentiation of AAH and PACG1,2 lesions, the differential diagnosis continues to be difficult in some cases, especially with needle biopsy material where a limited number of criteria can be evaluated. We feel that it is important to determine the histological parameters together in AAH lesions where basal cells are focal or few in numbers. Our results suggest that the combination of architectural and immunohistochemical features allows identification of AAH and accurate differentiation from PACG1,2 in most cases.

REFERENCES

1. Montironi R, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M. Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed neoplastic lesions in the prostate. Nat Clin Pract Urol 2007;4:321-32.
2. Chrisofos M, Papatsoris AG, Lazaris A, Deliveliotis C. Precursor lesions of prostate cancer. Crit Rev Clin Lab Sci 2007;44:243-70.
3. Anim JT, Erbahn BH, Sathar SA. Benign disorders of the prostate: A histopathological study. Ann Saudi Med 1998;18:22-7.
4. Stamatiou K, Nlevizos A, Natzar M, Mihas C, Mariolis A, Michalodimitrakis E, Sofras F. Associations among benign prostate hypertrophy, atypical adenomatous hyperplasia and latent carcinoma of the prostate. Asian J Androl 2007;9:229-33.
5. Lopez-Beltran A, Qian J, Montironi R, Luque RJ, Bostwick DG. Atypical adenomatous hyperplasia (adenosis) of the prostate: DNA ploidy analysis and immunophenotype. Int J Surg Pathol 2005;13:167-73.
6. Rekhi B, Jaswal TS, Arora B. Premalignant lesions of prostate and their association with nodular hyperplasia and carcinoma prostate. Indian J Cancer 2004;41:60-5.
7. Lopez-Betran A, Pacelli A, Qian J. Atypical adenomatous hyperplasia of the prostate. Mod Pathol 1996;9:77A.
8. Montironi R, Mazzucchelli R, Scarpelli M. Precancerous lesions and conditions of the prostate. : Differences in the structural features of AAH and PACG1,2. The largest gland diameter was in AAH in our study while the mean gland diameter was larger in PACG1,2 lesions. The results are similar with no statistical significance. We felt that these criteria could not be used in the differential diagnosis of AAH and PACG1,2 lesions.
adenocarcinoma and atypical adenomatous hyperplasia of the prostate. Cancer 1997;79:1172-9.

16. Bostwick DG. Prospective origins of prostate carcinoma: Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 1996;78:330-6.

17. Bostwick DG, Srigley J, Grignon D, Maskem J, Humphrey P, van der Kwast TH, et al. Atypical adenomatous hyperplasia of the prostate: Morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol 1993;24:819-32.

18. Brawn PN, Johnson EH, Speights VO, Riggs M, Lind M, Bell N. Long-term survival of stage A prostate carcinoma, atypical hyperplasia/adenosis and BPH. Br J Cancer 1994;69:1098-101.

19. Bostwick DG, Qian J. Atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 1995;19:506-18.

20. Quin J, Jenkins RB, Bostwick DG. Chromosomal anomalies in atypical adenomatous hyperplasia and carcinoma of the prostate using fluorescence in situ hybridization. Urology 1995;46:837-42.

21. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: Correlation of histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.

22. Lindeman N, Weidner N. Immunohistochemical profile of prostatic and urothelial carcinoma impact of heat-induced epitope retrieval and presentation of tumours with intermediate features. Appl Immunohistochem 1996;4:264-75.

23. Gaudin PB, Epstein JI. Adenosin of the prostate: Histologic features in transurethral resection specimens. Am J Surg Pathol 1994;18:863-70.

24. Gaudin PB, Epstein JI. Adenosin of the prostate: Histologic features in needle biopsy specimens. Am J Surg Pathol 1995;19:737-47.

25. Kramer CE, Epstein JI. Nucleoli in low-grade prostate adenocarcinoma and adenosin. Hum Pathol 1993;24:618-23.

26. Haussler O, Epstein JI, Amin MB, Heitz PU, Hailemariam S. Cell proliferation, apoptosis, oncogene and tumor suppressor gene status in adenosin with comparison to benign prostatic intraepithelial neoplasia and cancer. Hum Pathol 1999;30:1077-86.

27. Montironi R, Bartels PH, Hmlton PW, Thompson D. Atypical adenomatous hyperplasia (adenosis) of the prostate: Development of a bayesian belief network for its distinction from well-differentiated adenocarcinoma. Hum Pathol 1996;27:396-407.

28. Brawn PN, Speights VO, Contin JU, Bayardo RJ, Kuhl DL. Atypical hyperplasia in prostates of 20 to 40 year old men. J Clin Pathol 1989;42:383-6.

29. Gleason DF. Atypical hyperplasia, benign hyperplasia and well differentiated adenocarcinoma of the prostate. Am J Surg Pathol 1985;9:53-67.

30. Shah IA, Schlageter MO, Stinnett P, Lechago J. Cytokeratin immunohistochemistry as a diagnostic tool for distinguishing malignant from benign epithelial lesions of the prostate. Mod Pathol 1991; 4:220-4.

31. O’Malley FP, Grignon DJ, Shum DT. Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol 1990;417:191-6.

32. Ramnani DM, Bostwick DG. Basal cell-specific anti-keratin antibody 34ßE12: Optimizing its use in distinguishing benign prostate and cancer. Mod Pathol 1999;12:443-4.

33. Gleason D. Histological grading and clinical staging of carcinoma of the prostate, in urologic pathology. In: The prostate. Lea and Febiger: Philadelphia; 1977. p. 171-98.

34. Gleason DF. Histologic grading of prostate cancer: A perspective. Hum Pathol 1992;23:273-9.

35. Varma M, Linden MD, Amin MB. Effect of formalin fixation and epothe retrieval techniques on antibody 34ßE12 immunostaining of prostatic tissue. Mod Pathol 1999;12:472-8.

36. Yang XJ, Lee Wu C, Woda BA, Dresser K, Tretiakova M, Fanger GR. Expression of α methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 2002;26:921-5.

37. Mittal BV, Amin MD, Kinare SG. Spectrum of histologic lesions in 185 consecutive prostatic specimens. J Postgrad Med 1989;35:157-61.

38. Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in benign and neoplastic human prostate. Cancer Res 1985;45:5665-9.

39. Oliab KB, Kahane H, Epstein JL. Can basal cell be seen in adenocarcinoma of the prostate? An immuno-histochemical study using high molecular weight cytokeratin (Clone 34ßE12) antibody. Am J Surg Pathol 2002;26:1151-60.

40. Goope PB, McGinley KM. Fitzgibbon JF. Antikeratin antibody 34ßE12 staining in prostate carcinoma. Am J Clin Pathol 1997;107:219-23.

41. Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A. P504S: A new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001:25:1397-404.

42. Yang XJ, Lecksell K, Gaudin P, Epstein JL. Rare expression of high molecular-weight cytokeratin in adenocarcinoma of the prostate gland: A study of 100 cases of metastatic and locally advanced prostate cancer. Am J Surg Pathol 1999;23:147-52.

43. Chan YF, Epstein JL. Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology 1999;53:351-5.

44. Bostwick DG, Qian J. Atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 1995;19:506-18.

45. Rosai J. Atlas of tumor pathology. In: Young RH, Srigley JR, Amin MB, Ullbright TM, Cubillia AL, editors. Tumours of the prostate gland, seminal vesicles, male urethra and penis. Third Series Fascicle 28. Armed Forces Institute of Pathology: Washington D.C; 2000. p. 1-25.

46. Bostwick DG, Brawer ML. Prostatic intraepithelial neoplasia and early invasion in prostate cancer. Cancer 1987;59:788-94.

47. Ramnani DM, Bostwick DG. Basal cell-specific anti-keratin antibody 34ßE12: Optimizing its use in distinguishing benign prostate and cancer. Mod Pathol 1999;12:443-4.

48. Varma M, Linden MD, Amin MB. Effect of formalin fixation and epothe retrieval techniques on antibody 34ßE12 immunostaining of prostatic tissue. Mod Pathol 1999;12:472-8.

How to cite this article: Midi A, Tecimer T, Bozkurt S, Özkan N. Differences in the structural features of atypical adenomatous hyperplasia and low-grade prostatic adenocarcinoma. Indian J Urol 2008;169-177.

Source of Support: Nil, Conflict of Interest: None declared.